HBP vs. BCT, MBX, APS, RVX, ATE, TH, AEZS, SVA, ONC, and MDNA
Should you be buying Helix BioPharma stock or one of its competitors? The main competitors of Helix BioPharma include BriaCell Therapeutics (BCT), Microbix Biosystems (MBX), Aptose Biosciences (APS), Resverlogix (RVX), Antibe Therapeutics (ATE), Theratechnologies (TH), Aeterna Zentaris (AEZS), Sernova (SVA), Oncolytics Biotech (ONC), and Medicenna Therapeutics (MDNA). These companies are all part of the "biotechnology" industry.
Helix BioPharma (TSE:HBP) and BriaCell Therapeutics (TSE:BCT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment.
Helix BioPharma received 65 more outperform votes than BriaCell Therapeutics when rated by MarketBeat users. However, 100.00% of users gave BriaCell Therapeutics an outperform vote while only 63.46% of users gave Helix BioPharma an outperform vote.
In the previous week, Helix BioPharma had 1 more articles in the media than BriaCell Therapeutics. MarketBeat recorded 1 mentions for Helix BioPharma and 0 mentions for BriaCell Therapeutics. Helix BioPharma's average media sentiment score of 0.00 equaled BriaCell Therapeutics'average media sentiment score.
Helix BioPharma has a beta of -0.78, indicating that its share price is 178% less volatile than the S&P 500. Comparatively, BriaCell Therapeutics has a beta of 1.75, indicating that its share price is 75% more volatile than the S&P 500.
13.9% of BriaCell Therapeutics shares are owned by institutional investors. 20.5% of Helix BioPharma shares are owned by insiders. Comparatively, 12.3% of BriaCell Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Helix BioPharma's return on equity of 0.00% beat BriaCell Therapeutics' return on equity.
Helix BioPharma is trading at a lower price-to-earnings ratio than BriaCell Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Helix BioPharma and BriaCell Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.
Get Helix BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for HBP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Helix BioPharma Competitors List
Related Companies and Tools
